Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "CDC"

67 News Found

Pfizer and BioNTech receive FDA authorization for Omicron KP.2-adapted Covid-19 Vaccine
Drug Approval | August 23, 2024

Pfizer and BioNTech receive FDA authorization for Omicron KP.2-adapted Covid-19 Vaccine

The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older


Health Minister Nadda reviews Monkeypox situation and preparedness
Policy | August 19, 2024

Health Minister Nadda reviews Monkeypox situation and preparedness

Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management


Apollo Clinic launches nationwide vaccination campaign to tackle monsoon illnesses
Healthcare | August 08, 2024

Apollo Clinic launches nationwide vaccination campaign to tackle monsoon illnesses

Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics


DGHS, Health Ministry, along with experts reviews the Chandipura virus and AES cases in states
Public Health | July 22, 2024

DGHS, Health Ministry, along with experts reviews the Chandipura virus and AES cases in states

Multidisciplinary central team deployed to assist Gujarat with epidemiological, environmental, and laboratory investigations of AES cases


Health Ministry issues advisory to states in view of zika virus cases from Maharashtra
Policy | July 04, 2024

Health Ministry issues advisory to states in view of zika virus cases from Maharashtra

States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika


USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’
Diagnostic Center | June 14, 2024

USFDA approves expanded age indication for GSK’s RSV vaccine ‘Arexvy’

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes


Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast
Diagnostic Center | May 25, 2024

Zydus announces completion of Enrolment for Phase II clinical trial of Usnoflast

ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset


Moderna update on investigational RSV vaccine
Drug Approval | May 14, 2024

Moderna update on investigational RSV vaccine

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024


FDA approves Biktarvy label update with data for pregnant adults with HIV
Drug Approval | April 27, 2024

FDA approves Biktarvy label update with data for pregnant adults with HIV

Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV


GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA
Drug Approval | April 17, 2024

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by US FDA

Submission based on results from pivotal phase III trial showing all primary endpoints met